Monitor for the appointment of a permanent CFO and any subsequent updates on the company's financial reporting or capital markets activities. The interim CFO's familiarity with the company reduces near-term disruption risk, but a prolonged search could raise governance concerns for a clinical-stage issuer.
Price Chart
Executive Summary
Nasus Pharma announced the resignation of CFO Eyal Rubin, effective September 18, 2026, to pursue an opportunity outside life sciences. Director of Finance Oren Elmaliach has been appointed interim CFO. The departure is described as amicable and unrelated to any operational disagreement, but the loss of a key financial officer at a clinical-stage company introduces transitional risk.
Key Facts
- CFO Eyal Rubin resigns effective September 18, 2026.
- Resignation is not related to any disagreement with the company on operations, policies, or practices.
- Oren Elmaliach, Director of Finance, appointed interim CFO.
- Elmaliach has been with Nasus since inception and has over 15 years of financial experience.
- Nasus is a clinical-stage biopharmaceutical company with lead candidate NS002 (intranasal epinephrine for anaphylaxis).
Financial Impact
No financial figures provided in the filing. The CFO transition is a personnel change with no disclosed financial impact.
Risk Factors
- Transition risk during CFO search could distract from pipeline execution.
- Interim CFO may lack the external investor relations experience of the departing CFO.
- No permanent successor named, creating uncertainty about long-term financial leadership.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-039148 |
| Exhibit: ex99-1.htm | 0001493152-26-039148 |
| Document: 0001493152-26-039148-index-headers.html | 0001493152-26-039148 |
| Document: 0001493152-26-039148-index.html | 0001493152-26-039148 |
| Document: 0001493152-26-039148.txt | 0001493152-26-039148 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.51 | awaiting T+20 | — | $3.37 (−4.13%) |
Sep 23, 2026 4w ago | 3 | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.37 (−7.55%) |
Sep 18, 2026 5w ago | 424B5 | $3.44 $3.21 | ▲ +6.83% | ▲ +5.92% | $3.37 (+2.18%) |
Sep 14, 2026 6w ago | 6-K | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.37 (−7.81%) |
Sep 14, 2026 6w ago | EFFECT | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.37 (−7.81%) |
Aug 21, 2026 9w ago | EFFECT | $4.00 $3.44 | ▼ −14.00% | ▼ −13.47% | $3.37 (−15.87%) |
Aug 19, 2026 9w ago | 6-K | $3.84 $3.53 | ▼ −8.07% | ▼ −6.12% | $3.37 (−12.37%) |
Aug 17, 2026 10w ago | 6-K | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.37 (−9.05%) |
Aug 17, 2026 10w ago | Press Release | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.37 (−9.05%) |
Apr 1, 2026 29w ago | EFFECT | $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $3.37 (−31.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers